Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
International Journal of Molecular Sciences · 13.04.2023 · 24 (8) · 7235
DOI: 10.3390/ijms24087235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.04.2023. Verfasst von Joanna Szczepanek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Torun, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modifying enzymes, and mRNA regulators (such as miRNA mimics and antagomiRs) can reverse these alterations. Therefore, these epigenetic-targeting drugs are promising candidates for cancer treatment. However, there is currently no effective epi-drug monotherapy for breast cancer. Combining epigenetic drugs with conventional therapies has yielded positive outcomes and may be a promising strategy for breast cancer therapy. DNA methyltransferase inhibitors, such as azacitidine, and histone deacetylase inhibitors, such as vorinostat, have been used in combination with chemotherapy to treat breast cancer. miRNA regulators, such as miRNA mimics and antagomiRs, can alter the expression of specific genes involved in cancer development. miRNA mimics, such as miR-34, have been used to inhibit tumor growth, while antagomiRs, such as anti-miR-10b, have been used to inhibit metastasis. The development of epi-drugs that target specific epigenetic changes may lead to more effective monotherapy options in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Torun, Poland.
- Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, 87-100 Torun, Poland.
- Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Torun, Poland.
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland.
ORCID-Profile: Joanna Szczepanek, Monika Skorupa, Andrzej Tretyn
Zitieren
APA
Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Cybulski, C., & Tretyn, A. (2023). Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. International Journal of Molecular Sciences, 24(8), 7235. https://doi.org/10.3390/ijms24087235
Vancouver
Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Cybulski C, Tretyn A. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. International Journal of Molecular Sciences. 2023;24(8):7235. doi:10.3390/ijms24087235
BibTeX
@article{Szczepanek2023,
author = {Szczepanek, Joanna and Skorupa, Monika and Jarkiewicz-Tretyn, Joanna and Cybulski, Cezary and Tretyn, Andrzej},
title = {Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7235},
doi = {10.3390/ijms24087235}
}
EUVIMED